Genova Biotech To Launch New Anti-cancer Drug Novaferon
This article was originally published in PharmAsia News
Executive Summary
Beijing-based Genova Biotech will complete clinical trials on its anti-cancer drug Novaferon and commence production within the year. The company disclosed that it will price the genetically engineered protein-based product at a level only one-fifth to one-tenth that of imported biopharmaceutical medicines. Although it is still in the final approval stages, the drug's projected sales could reach several billion yuan. Novaferon's anti-tumor and anti-virus activities are much higher than those of natural interferon. Trials show that the drug can inhibit the growth of cancer of the pancreas, bowel, liver, lung, breast, ovary and prostate. (Click here for more - Chinese Language)
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.